Fierce Biotech

1. KSQ boosts PARP inhibition in animal models of ovarian and breast cancers with USP1 inhibitor

   KSQ boosts PARP inhibition in animal models of ovarian and breast cancers with USP1 inhibitor arlene.weintraub Fri, 10/23/2020 - 10:03

2. Alnylam makes case for lumasiran in infants ahead of FDA ruling  

   Alnylam makes case for lumasiran in infants ahead of FDA ruling   ntaylor Fri, 10/23/2020 - 08:29

3. Sirnaomics nabs a major $105M funding round for next stage of its RNA work

   Sirnaomics nabs a major $105M funding round for next stage of its RNA work badams Fri, 10/23/2020 - 07:55

4. Convalescent plasma fails phase 2 in moderate COVID-19 patients

   Convalescent plasma fails phase 2 in moderate COVID-19 patients ntaylor Fri, 10/23/2020 - 05:27

5. Retrophin buys up Orphan Technologies, spending $90M on rare disease drug

   Retrophin buys up Orphan Technologies, spending $90M on rare disease drug badams Fri, 10/23/2020 - 05:07